ATP6AP1 and fatty liver disease: While it was recently reported that low-dose metformin activates lysosomal AMPK via the PEN2-ATP6AP1 axis, thereby reducing hepatic steatosis in an HFD model (57), we did not observe indicators that AMPK was activated at the study endpoint (Supplemental Fig. S1C).